{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["106"],"submitter":["Pasquali S"],"pubmed_abstract":["<h4>Background</h4>Anthracycline-based neoadjuvant chemotherapy (NAC) may modify tumour immune infiltrate. This study characterized immune infiltrate spatial distribution after NAC in primary high-risk soft tissue sarcomas (STS) and investigate association with prognosis.<h4>Methods</h4>The ISG-STS 1001 trial randomized STS patients to anthracycline plus ifosfamide (AI) or a histology-tailored (HT) NAC. Four areas of tumour specimens were sampled: the area showing the highest lymphocyte infiltrate (HI) at H&E; the area with lack of post-treatment changes (highest grade, HG); the area with post-treatment changes (lowest grade, LG); and the tumour edge (TE). CD3, CD8, PD-1, CD20, FOXP3, and CD163 were analyzed at immunohistochemistry and digital pathology. A machine learning method was used "],"journal":["EBioMedicine"],"pagination":["105220"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11287012"],"repository":["biostudies-literature"],"pubmed_title":["Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy."],"pmcid":["PMC11287012"],"pubmed_authors":["Quagliuolo V","Dei Tos AP","Stacchiotti S","Brich S","Palmerini E","Beveridge RD","Vergani B","Lopez-Pousa A","Vallacchi V","Martin-Broto J","Coindre JM","Casiraghi E","Renne SL","Casali PG","Lalli L","Rivoltini L","Bague S","Romagosa C","Grignani G","Barisella M","Pasquali S","Sbaraglia M","Gronchi A","Bergamaschi L","Blay JY","Collini P"],"additional_accession":[]},"is_claimable":false,"name":"Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy.","description":"<h4>Background</h4>Anthracycline-based neoadjuvant chemotherapy (NAC) may modify tumour immune infiltrate. This study characterized immune infiltrate spatial distribution after NAC in primary high-risk soft tissue sarcomas (STS) and investigate association with prognosis.<h4>Methods</h4>The ISG-STS 1001 trial randomized STS patients to anthracycline plus ifosfamide (AI) or a histology-tailored (HT) NAC. Four areas of tumour specimens were sampled: the area showing the highest lymphocyte infiltrate (HI) at H&E; the area with lack of post-treatment changes (highest grade, HG); the area with post-treatment changes (lowest grade, LG); and the tumour edge (TE). CD3, CD8, PD-1, CD20, FOXP3, and CD163 were analyzed at immunohistochemistry and digital pathology. A machine learning method was used ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-06-02T09:19:09.569Z","creation":"2026-04-16T03:13:14.373Z"},"accession":"S-EPMC11287012","cross_references":{"pubmed":["39018755"],"doi":["10.1016/j.ebiom.2024.105220"]}}